Assay News and Research

RSS

Affymetrix commences shipment of gene profiling reagents

Affymetrix, Inc. today began shipping its FDA-cleared Gene Profiling Reagents. Affymetrix also announced the availability of the new Gene Profiling Array cGMP U133 P2, a version of the widely cited Human Genome U133 Plus 2.0 Array, as another component to its GeneChip Instrument System, which is used by Affymetrix partners for assay development.

12 Jul 2011

New genetic research on Ankylosing Spondylitis

The team of researchers from the Universities of Bristol, Queensland, Oxford, Texas and Toronto, used a technique called genome-wide association where millions of genetic markers are measured in thousands of people that have the disease and thousands of healthy individuals.

11 Jul 2011

Two defective genes may cause telomere elongations in cancer cells: Study

Scientists at Johns Hopkins have provided more clues to one of the least understood phenomena in some cancers: why the "ends caps" of cellular DNA, called telomeres, lengthen instead of shorten.

1 Jul 2011

Roche introduces new real-time PCR system

With "Size: Reduced. Fun: Amplified.", Roche Applied Science launched its new real-time PCR system on June 27th, 2011. The small, silent, sleek LightCycler Nano Instrument supports state-of-the-art technology for fast PCR protocols featuring leading edge thermal resolution and reproducibility.

1 Jul 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

Conventional Estrogen Receptor measurement methods may result in 10-20% false negative rate

A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.

28 Jun 2011

Inefficiency of activation-induced deoxycytidine deaminase is good for the immune system

Why is antibody diversity important? Think about it like this, said Myron Goodman, who is an author on the paper: "Why don't you die when I sneeze? It's because you have a powerful immune system. And the way to get a decent immune system is for your body to have a way to respond to insults it has never seen before."

28 Jun 2011

Polymedco launches BTA stat test for detection of recurrent bladder cancer

Polymedco, Inc. is pleased to announce the direct availability of the BTA stat® test from our sales force – The BTA stat® test is a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor associated antigen in urine.

27 Jun 2011

McMaster researchers to use tiny worms for Parkinson's project

McMaster researchers from three disciplines are deploying thousands of tiny worms and a homegrown invention to test drugs in a collaborative bid to defeat Parkinson's Disease.

27 Jun 2011

VENENUM opens new medicinal chemistry facility in Hamilton, NJ

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify potential therapeutic agents against its novel disease-based targets, or its partners' targets, announced today that it opened its new medicinal chemistry space at 8 Black Forest Road in Hamilton, NJ.

22 Jun 2011

NextGen launches first CSF multiplex protein assay for detecting CNS diseases

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification.

21 Jun 2011

Free ADAP 2.0 software upgrade with Biochrom's EZ Read 400 research reader

Busy laboratory environments require a microplate reader with the flexibility to cover many assay types, and software that delivers fast, reliable analysis. With this in mind, Biochrom are offering a free software upgrade from ADAP 2.0 Basic to ADAP 2.0 Plus with purchases of the EZ Read 400 research reader until 30 September 2011. For further information, visit www.biochrom.co.uk.

From Biochrom Ltd. 20 Jun 2011

Randox launches automated laboratory assay for Heart-type Fatty Acid Binding Protein

Randox Laboratories, the international clinical diagnostics company, has today launched an automated laboratory assay for Heart-type Fatty Acid Binding Protein (H-FABP), to improve the diagnosis and management of patients with suspected acute coronary syndrome (ACS).

From Randox Laboratories Ltd. 20 Jun 2011

Roche RTCA HT Instrument allows fully-automated impedance screens for GPCRs

Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the measurement of G protein-coupled receptor (GPCR) activation electrical impedance represents an excellent universal readout technology, since different signaling pathways can be measured in one assay format using recombinant as well as primary cells.

17 Jun 2011

USPTO issues patent for Predictive Biosciences' multiple biomarker assay

Predictive Biosciences, a provider of novel molecular diagnostic tests, announced that on June 7, 2011 the U.S. Patent and Trademark Office issued Patent Number 7,955,822 for "Detection of Nucleic Acids and Proteins".

17 Jun 2011

Cambridge Biomedical, Neogenix partner to develop ELISA assays for pancreatic and colorectal cancer

Neogenix Oncology, Inc. is pleased to announce it has signed an agreement with Cambridge Biomedical, Inc, based in Boston, MA, for the development of its pancreatic and colorectal cancer diagnostic serum ELISA assays.

16 Jun 2011

ProImmune introduces new uniquely powerful protein and peptide array platform

ProImmune Ltd., a leader in services for understanding immune responses, announced today that it has launched ProArray Ultra, a uniquely powerful protein and peptide array platform, which is more sensitive than optimized ECL ELISA.

16 Jun 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

Cancer diagnostics company Biomoda, Inc. received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath assay to include patient response to cancer therapy during the treatment phase of the disease.

15 Jun 2011

Response Biomedical NTproBNP Assay does not meet FDA regulatory criteria for CLIA waiver

Response Biomedical Corporation announced that it has received a notification from the U.S. Food and Drug Administration (FDA) that its NTproBNP Assay did not meet the criteria to obtain a waiver under the Clinical Laboratory Improvement Amendments of 1988.

14 Jun 2011